Company: ARWR
Filing Date: 2025-01-29
Form Type: DEF 14A
Source: 0001628280-25-002848
Chunk: 39

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-01-29
Form: DEF 14A
Chunk 39
---
25x to 4.0x our market capitalization at the time of the peer selection; and • Companies with between 92 to 1,311 employees. The compensation peer group was selected in such a manner that our market capitalization was very near the median for all peer companies. Consideration was also given to the frequency or infrequency with which a company was identified as a peer with other peer companies. For fiscal 2024, the compensation peer group was generated in the first quarter of fiscal 2024 and consisted of the following companies:

| ACADIA Pharmaceuticals, Inc. |     | Insmed                     |
| Amicus Therapeutics          |     | Intellia Therapeutics      |
| Apellis Pharmaceuticals      |     | Ionis Pharmaceuticals      |
| Arcus Biosciences            |     | Ironwood Pharmaceuticals   |
| BioCryst Pharmaceuticals     |     | Mirati Therapeutcis        |
| Blueprint Medicines          |     | Madrigal Pharmaceuticals   |
| BridgeBio Pharma             |     | REGENXBIO                  |
| CRISPR Therapeutics AG       |     | Sarepta Therapeutics       |
| Deciphera Pharmaceuticals    |     | Ultragenyx Pharmaceuticals |
| Denali Therapeutics          |     | Vir Biotechnology          |
| Halozyme Therapeutics        |     |                            |

BioCryst Pharmaceuticals, Deciphera Pharmaceuticals, Ironwood Pharmaceuticals, and Madrigal Pharmaceuticals were added to the compensation peer group and Chemo Centryx, FibroGen, Novavax, amd Reata Pharmaceuticals were removed from the compensation peer group due to changes in our business complexity, employee base and market capitalization, as well as mergers, changes to business complexity, employee base and market capitalization among our prior peer group. The compensation study prepared by Compensia and presented in October 2023 provided an assessment of our compensation practices as compared to industry peers. Compensation levels for our executive officers, in the aggregate, were determined to be within the range of compensation provided to similarly placed executives and consistent with our compensation philosophy. Individual Compensation Elements In 2024, the principal elements of our executive compensation program were as follows: • base salary; • an annual cash incentive compensation opportunity; • long-term incentive compensation in the form of equity awards; • welfare and health benefits; and • post-employment compensation arrangements. Base Salary Base salary represents the fixed portion of the compensation of our executive officers, including our NEOs, and is an important element of compensation intended to attract